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Objectives: Febrile urinary tract infections (fUTI) can often be treated safely with oral antimicrobials 
in an outpatient setting. However, a minority of patients develop complications that may progress into 
septic shock. An accurate assessment of disease severity upon emergency department (ED) presentation 
is therefore crucial in order to guide the most appropriate triage and treatment decisions. 
Methods: Consecutive patients were enrolled with presumptive fUTI across 7 EDs in the Netherlands. The 
biomarkers mid-regional proadrenomedullin (MR-proADM), procalcitonin (PCT), C-reactive protein (CRP), 
and a clinical score (PRACTICE), were compared in their ability to predict a clinically severe course of 
fUTI, initial hospital admission and subsequent readmission using area under the receiver operating char- 
acteristic (AUROC) curves. 
Results: Biomarker concentrations were measured in 313 patients, with 259 (83%) hospitalized upon ED 
presentation, and 54 (17%) treated as outpatients. Of these outpatients, 12 (22%) were later hospital- 
ized. MR-proADM had the highest diagnostic accuracy for predicting a complicated fUTI (AUROC [95% CI]: 
0.86 [0.79–0.92]), followed by PCT (AUROC [95% CI]: 0.69 [0.58–0.80]). MR-proADM concentrations were 
unique in being significantly elevated in patients directly admitted and in outpatients requiring subse- 
quent hospitalization, compared to those completing treatment at home. A virtual triage algorithm with 
an MR-proADM cut-off of 0.80 nmol/L resulted in a hospitalization rate of 66%, with only 2% secondary 
admissions. 
Conclusion: MR-proADM could accurately predict a severe course in patients with fUTI, and identify 
greater patient numbers who could be safely managed as outpatients. An initial assessment on ED pre- 
sentation may focus resources to patients with highest disease severities. 
© 2018 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) Abbreviations: BP, blood pressure; BPM, beats per minute; CRP, C-reactive pro- 
tein; ED, emergency department; FUTI, febrile urinary tract infection; CI, confi- 
dence interval; ICU, intensive care unit; IQR, interquartile range; PCT, procalcitonin; 
PRACTICE, Prediction Rule for Admission policy in Complicated urinary Tract InfeC- 
tion LEiden; MR-proADM, mid-regional proadrenomedullin; ROC, receiver operating 
characteristics curves; AUC, area under the curve; SD, standard deviation. 
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nd usually result in a mild, low severity illness. Nevertheless,
hese conditions may rapidly develop in a minority of patients
nto a life-threatening condition, such as septic shock or multi-
le organ failure. Due to this potential risk, many patients are
nitially hospitalized, leading to a potential over treatment of
ow severity patients and increased healthcare costs. 1,2 Previous
tudies, however, have found that uncomplicated pyelonephritis in
omen can be safely treated at home with oral antibiotics, 3 whilst
lderly patients, men and those with comorbidities may also be
otentially eligible for outpatient treatment. 4 
It is therefore surprising that no tools have been established
o rapidly identify UTI disease severity on ED admission, unlike
he specialized scores such as CURB-65 and PSI developed for
ommunity acquired pneumonia. 5 Recently, we assessed the use
f a clinical score – the Prediction Rule for Admission policy in
omplicated urinary Tract InfeCtion LEiden (PRACTICE) – to guide
dmission policy in a randomized clinical trial of fUTI patients.
lthough implementation of this score resulted in a decrease in
ospital admissions, a subsequent readmission rate of more than
5% was observed in patients who were initially discharged. 6 
onsequently, more accurate tools of disease severity are required
o not only assess the requirement for initial hospitalization, but
o also prevent subsequent readmissions. 
The use of blood biomarkers has shown considerable promise
n resolving this unmet clinical requirement in several infectious
iseases. In adults with community acquired UTI, procalcitonin
PCT) has been shown to be an accurate marker of bacteremia, 7–9 
hilst mid-regional proadrenomedullin (MR-proADM) has been
hown to strongly predict a complicated course of treatment, the
eed for ICU admission, as well as identifying patients at risk of
ortality. 10,11 Consequently, a combination of these biomarkers, or
heir use in isolation, may aid in determining the most appropriate
etting for treatment. 
This study therefore enrolled patients presenting to the emer-
ency department with febrile urinary tract infections (fUTI), and
imed to compare the performance of biomarkers (MR-proADM,
CT and CRP) with the existing clinical score (PRACTICE) in order
o (i) assess initial fUTI disease severity, (ii) predict the require-
ent for hospitalization, and (iii) predict the readmission rate in
atients initially selected for outpatient treatment. 
ethods 
esign and study population 
This was a secondary analysis of the Hospitalization for
ommunity-acquired febrile urinary tract infection: validation and
mpact assessment of a clinical prediction rule study 6 ; a stepped
edge cluster-randomized trial involving consecutive patients
resenting with a presumptive diagnosis of fUTI at the emergency
epartments of 7 hospitals in the Netherlands, between January
010 and June 2014. 
All participating centers started with a control period, in which
outine clinical practice regarding hospitalization policy was ap-
lied. The intervention (use of the PRACTICE) was introduced at
he participating centers sequentially, in random order. By the end
f the allocation all sites, except one, used the PRACTICE to guide
dmission policy. The PRACTICE is a prediction rule allocating
oints to age, sex, nursing home residency, comorbidities, and
ital signs at presentation (see Supplementary Table 1). The score
anges from 8 to > 125 points and is divided into the following
isk classes: low < 75 points (recommendation towards ambulant
are); intermediate 75–100 points (consider ambulant care); high
 100 points (recommendation towards hospital admission), based
n the validation cohort. 6 Inclusion criteria were age ≥18 years, fever ( ≥38.0 °C) and/or a
istory of fever or shaking chills within 24 h before presentation,
 positive nitrite dipstick test or leukocyturia, and at least one
ymptom of UTI (dysuria, perineal pain or flank pain). Exclusion
riteria included pregnancy, hemo- or peritoneal-dialysis, and a
istory of kidney transplantation or polycystic kidney disease. In
he current analysis, only patients with blood samples available
or biomarker analysis were included (Supplementary Appendix
ig. S1). The study protocol was approved by the local ethical
ommittee, and written informed consent was obtained from all
articipants. The original study was monitored by a data safety
onitoring board and was stopped prematurely on their advice,
ue to the rate of secondary admissions in the interventional
roup exceeding the predefined stopping criterion. 6 
iomarker and clinical score measurements 
CRP was measured at the local laboratories upon patient enroll-
ent using an immunoturbidimetric assay, with cut-offs varying
rom 5 to 10 mg/L. Surplus EDTA plasma samples were addi-
ionally collected, centrifuged and stored at −80 °C within 2 h of
atient enrollment. MR-proADM and PCT were batch-measured in
 blinded fashion by TRACE technology (Time Resolved Amplified
ryptate Emission) using a new sandwich immunoassay (Kryptor
ompact Plus Analyzer, BRAHMS, Hennigsdorf, Germany), with a
imit of detection of 0.05 nmol/L and 0.02 ng/L, respectively. The
RACTICE score (Supplementary Appendix Table S1) was calculated
n the total patient population, regardless of whether they were
nrolled as part of the control or interventional group in the
riginal study. 6 
ndpoints 
Severe course of febrile urinary tract infection was defined
s a composite of all-cause 30-day mortality, intensive care unit
ICU) admission, and extended hospitalization ( > 10 days). Patient
isposition was noted upon initial ED presentation, and classified
s either being (i) admitted for hospital treatment, (ii) discharged
or outpatient treatment, or (iii) admitted for treatment after
nitial outpatient therapy. 
tatistical analysis 
Descriptive statistics are expressed as counts (percentage),
eans (standard deviation) or medians [first quartile – third
uartile], as appropriate. Biomarker values were log-normalized
efore analysis. Univariate analysis was performed using ANOVA,
tudent’s t -test or Mann–Whitney U test for continuous vari-
bles, and Chi-square test for categorical variables. Area under
he receiver operating characteristics (AUROC) curves with 95%
onfidence intervals [95% CI] were used to compare the predictive
alue of the biomarkers and clinical score. Differences between
UROCs were assessed using DeLong’s test for significance. 12 
Based on disease severity observations, biomarker suitability
or guiding triage decisions was further investigated. Biomarker
oncentrations in relation to predetermined cut-offs allowed pa-
ients to be allocated to either virtual hospitalization or outpatient
reatment groups. Patients allocated to outpatient care who were
ater hospitalized were counted as readmissions. The virtual ad-
ission and readmission rates, as well as instances of bacteremia,
CU admission and 30-day mortality were subsequently calculated.
 p -value of < 0.05 was considered statistically significant. SPSS
oftware (SPSS Inc. Chicago, version 23.0) was used for statistical
nalysis. 
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Table 1 
Patient characteristics and outcome. 
Patient characteristics Control group Intervention group Total 
( N = 185) ( N = 128) ( N = 313) 
Age in years; median (IQR) 58 (40–73) 61 (42–76) 58 (40–75) 
Sex – female 117 (63) 69 (54) 186 (59) 
Febrile uncomplicated UTI 45 (24) 28 (22) 73 (23) 
Antimicrobial pre-treatment at inclusion 73 (39) 41 (32) 114 (36) 
Urologic history 
Present urinary catheter 11 (6) 9 (7) 20 (6) 
History of urinary tract disorder 58 (31) 33 (26) 91 (29) 
Co-morbidities 
Any 94 (51) 76 (59) 170 (54) 
Diabetes mellitus 24 (13) 29 (23) 53 (17) 
Malignancy 10 (5) 11 (9) 21 (7) 
Heart failure 22 (12) 12 (9) 34 (11) 
Cerebrovascular disease 10 (5) 20 (16) 30 (10) 
Cirrhosis 1 (0) 2 (2) 3 (1) 
Renal insufficiency 8 (4) 20 (16) 28 (9) 
Immunocompromised 11 (6) 10 (8) 21 (7) 
Presentation 
Shaking chills 124 (67) 92 (72) 216 (69) 
Systolic BP (mmHg), mean ± SD 130 ± 22 132 ± 22 130 ± 22 
Diastolic BP (mmHg), mean ± SD 71 ± 14 74 ± 14 72 ± 14 
Heart rate (b.p.m.), mean ± SD 96 ± 18 98 ± 18 97 ± 14 
Fever duration at presentation, median hours [IQR] 28 [12–72] 24 [12–48] 24 [12–72] 
Need for percutaneous nephrostomy 5 (3) 4 (3) 9 (3) 
Outcome 
Hospitalization 
Total hospitalization 169 (91) ∗ 102 (80) ∗ 271 (87) 
– Primary admission 167 (90) ∗ 92 (72) ∗ 259 (83) 
– Outpatient treatment 18 (10) ∗ 36 (28) ∗ 54 (17) 
– Readmission 2/18 (11) 10/36 (28) 12/54 (22) 
Mortality 
– 30-day mortality 2 (1) 3 (2) 5 (2) 
– 90-day mortality 3 (2) 5 (4) 8 (3) 
Need for ICU admission 8 (4) 1 (1) 9 (3) 
Hospital admission > 10 days 11 (6) 10 (8) 21 (7) 
Length of hospital stay [median; IQR] 5; 4–7 5; 3–6 5; 4–7 
Severe course of fUTI 22 (9) 12 (9) 34 (9) 
Bacteremia 44/177 (25) 30/125 (24) 74/302 (24) 
Clinical cure 146/165 (79) 94/117 (80) 240/282 (85) 
Microbiological cure 139/154 (90) 102/108 (94) 241/262 (92) 
Data are presented as n (%) unless stated otherwise. BP: blood pressure. SD: standard deviation. Bpm: beats per 
minute. IQR: interquartile range. Readmission: after initial outpatient treatment. ICU: intensive care unit. 
∗ p < 0.05. Severe course: composite of 30-day mortality, need for ICU-admission or > 10 days hospitalization. 







































[  Results 
A total of 313 patients with a presumptive diagnosis of fUTI
were analyzed (details provided in the Flowchart in the Sup-
plementary Appendix Fig. S1). Patient characteristics in terms
of urologic history, comorbidities and presenting symptoms are
outlined in Table 1 . The 30-day mortality rate across the total
population was 2% ( N = 5), with 114 (36%) patients undergoing
existing antimicrobial treatment prior to ED presentation. Patients
had an average age of 58 (40–75) years, with females comprising
the majority of enrolled patients ( N = 186; 59%). 
Upon presentation to the ED, 259 (83%) patients were hospi-
talized, with 54 (17%) selected for outpatient treatment. Of these
outpatients, 12 (22%) subsequently re-presented to the ED and
were hospitalized. Bacteremia was found in 74 (24%) patients
(Supplementary Appendix Table S2), and 9 (3%) patients were
admitted onto the ICU. Median biomarker concentrations across
the total patient population were as follows: MR-proADM: 1.0
[0.71–1.54] nmol/L; PCT: 0.60 [0.16–2.5] μg/mL; and CRP: 115 (52–
199) mg/L. Both MR-proADM and PCT were significantly correlated
to the PRACTICE score ( p < 0.001), albeit weakly ( R 2 = 0.28 and
0.05, respectively; Supplementary Appendix Fig. S2). There was
no significant correlation between the PRACTICE score and CRP
concentrations. disease severity: the prediction of severe course of fUTI 
The performance of individual biomarkers and the PRACTICE
core in predicting a severe course of treatment was assessed
sing AUROC analysis ( Fig. 1 ). MR-proADM exhibited the strongest
erformance (AUROC [95% CI]: 0.86 [0.79–0.92]), which was signif-
cantly greater than that of PCT (AUROC [95% CI]: 0.69 [0.58–0.80];
 < 0.001) and CRP (AUROC [95% CI]: 0.55 [0.44–0.66]; p < 0.001).
here were no significant differences between the performance of
R-proADM and the PRACTICE score (AUROC [95% CI]: 0.80 [0.74–
.87]). The combination of MR-proADM, PCT or PRACTICE with one
nother did not significantly increase predictive ability more than
he use of MR-proADM alone (e.g. MR-proADM + PRACTICE: AU-
OC [95% CI]: 0.88 [0.82–0.93]; Supplementary Appendix Table S3).
rediction of the need for hospital admission in the total population 
Biomarker measurements upon presentation to the ED ( Fig. 2 )
ound significantly higher concentrations of MR-proADM and
CT in patients who were hospitalized compared to those who
ere treated as outpatients (MR-proADM: 1.05 [0.73–1.61] vs.
.83 [0.57–1.15] nmol/L, p < 0.01; PCT: 0.68 [0.20–2.69] vs. 0.29
0.13–1.07] μg/mL, p < 0.05). Conversely, there were no significant
ifferences in CRP concentrations between the two groups. 
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Fig. 1. Biomarker and clinical score accuracy in the prediction of a severe course of 
fUTI. 
proADM : Mid-regional proadrenomedullin; PCT : Procalcitonin; CRP : C-reactive pro- 















































AUROC analysis indicated that the PRACTICE score had the
ighest accuracy in predicting the need for hospitalization (AUROC
95% CI]: 0.72 [0.64–0.79]), although there were no significant
ifferences com pared to the performance of either MR-proADM
r PCT (AUROC [95% CI]: 0.68 [0.60–0.76] and 0.63 [0.54–0.72],
espectively; Supplementary Appendix Fig. S3). Furthermore,
here were no significant improvements in accuracy when MR-
roADM, PCT or the PRACTICE score were combined in any order
Supplementary Appendix Table S4). 
rediction of hospitalization in the outpatient population 
Interestingly, in the subgroup of patients that were initially
reated as outpatients but who later re-presented to the emer-ig. 2. Biomarker concentrations in different patient treatment settings. 
istribution of (a) MR-proADM, (b) PCT and (c) CRP in patients treated as who completed
reatment, and patients who were hospitalized from the start of treatment. ∗ p < 0.05; ∗∗ency department and were hospitalized, MR-proADM concentra-
ions were significantly elevated upon initial presentation (1.21
0.81–1.86] nmol/L) compared to those who completed outpatient
reatment at home (0.78 [0.55–1.02] nmol/L; p < 0.01). There
ere no significant differences in either PCT or CRP concentrations
etween the two groups. 
AUROC analysis for the prediction of hospitalization in patients
ho were initially deemed suitable for outpatient treatment found
hat MR-proADM had the greatest performance (AUROC [95% CI]:
.74 [0.58–0.90]) followed by the PRACTICE score (AUROC [95% CI]:
.72 [0.52–0.91]), although differences were not significant (Sup-
lementary Appendix Fig. S4). There was no significant association
sing either PCT or CRP. 
otential effects on triage decisions 
Based on the previous analysis, MR-proADM was chosen for
he virtual biomarker guided treatment allocation. Four different
ut-off values were subsequently used based on those found
n the literature, which included: 0.55 nmol/L 13 ; 0.80 nmol/L;
.0 nmol/L 10 ; and 1.25 nmol/L. 
The potential impact of this virtual triage algorithm on both
ospitalization and outpatient treatment decisions is shown
n Fig. 3 . Compared to the actual hospitalization rate of 83%
 N = 259), a decreased hospitalization rate of 66%, 49% and
4% could be found at MR-proADM cut-offs of 0.80, 1.0 and
.25 nmol/L, respectively. Only at the lowest cut-off of 0.55 nmol/L,
id the hospitalization rate (86%) exceed that of the actual hos-
italization rate. Interestingly, the secondary admission rate at
ll MR-proADM cut-offs did not exceed 3%, compared to the
ctual readmission rate of 22%. PCT and CRP had less value in
he virtual triage, since commonly used cut-off points did not
ower the primary admission rate when compared to MR-proADM, treatment as an outpatient, patients who were hospitalized after initial outpatient 
p < 0.01. 
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Fig. 3. 10 × 10 dot plot of virtual triage based on MR-proADM at different cut off levels. 
Data are presented as n . Admission: hospitalization after initial outpatient treatment; n = 12 in all patients. Bacteremia: n = 74 in all patients. ICU: admission on Intensive 
Care Unit, n = 9 in all patients. Mortality: assessed at day 30; n = 5 (all admitted to hospital in each of the triage scenarios). proADM : mid-regional proadrenomedullin. 
Fig. 4. Comparisons of hospital admission and outpatient admission in different triage models. 
(a) Conventional triage in control period. (b) PRACTICE guided triage. (c) Virtual triage algorithm based on an MR-proADM with cut off 0.8 nmol/L. ED : emergency department. 




























without assigning outpatient treatment to patients with actual ICU
admission or mortality within 30 days. 
In comparison to the conventional hospital triage and inter-
ventional PRACTICE guided triage arms of the original study, MR-
proADM guided triage at a cut-off of 0.80 nmol/L could decrease
initial hospital admissions from 90% and 72%, respectively, to 66%
( Fig. 4 ). Furthermore, outpatient readmissions could also be de-
creased from 11% in the conventional triage and 28% in the PRAC-
TICE guided triage, to 2% in the virtual MR-proADM guided triage. 
Discussion 
This study highlights the ability of MR-proADM in accurately
predicting a severe course of febrile urinary tract infection (fUTI)
in patients presenting to the emergency department (ED), and in
turn, demonstrates its potential use in safely decreasing emer-ency department admissions, increasing outpatient numbers, and
owering subsequent outpatient hospitalization. 
Urinary tract infections are the second most frequent infection
iagnosed within the ED, 14 and many patients with low disease
everities are hospitalized due to concerns regarding infectious
rogression towards sepsis, septic shock and multiple organ
ailure. Indeed, 20–30% of all sepsis cases originate in the urogen-
tal tract, 15 and despite relatively low mortality rates compared to
ther origins of septic shock, deaths due to urosepsis can still reach
p to 60% in specific patient groups. 16 Conversely, the unnecessary
ospitalization of low disease severity patients can result in poten-
ial overcrowding and overtreatment issues, subsequently leading
o an increase in associated clinical costs. An accurate assessment
f initial disease severity and likelihood of disease progression,
herefore, are crucial in order to facilitate a more personalized
atient treatment strategy at the most appropriate setting. 


































































































































f  This study therefore compared the use of commonly used
iomarkers, such as procalcitonin (PCT) and C-reactive protein
CRP), and a pre-established clinical score (PRACTICE), 6 with that
f mid-regional proadrenomedullin (MR-proADM) in order to
redict a severe course of fUTI, and provide an appropriate model
f triage. MR-proADM was found to be the most accurate param-
ter in identifying patients at risk of a severe course, which was
ignificantly greater than that of either PCT or CRP. Similar results
n a previous study of fUTI patients 10 found that MR-proADM
erformance was also greater than that of either PCT or CRP
n predicting 30 day mortality, and indeed, confirm the lack of
rognostic ability of CRP found within this study. 
Whilst only a limited number of studies have investigated MR-
roADM performance in urinary tract infections, numerous studies
ave been conducted in patients with lower respiratory tract
nfections (LRTI). In accordance with the findings of our study, the
se of MR-proADM as a stand-alone parameter in LRTI patients
as been shown to have either a greater or comparable accuracy
n predicting mortality or the development of adverse events com-
ared to established clinical scores, such as CURB-65 or PSI. 17–27 
umerous clinical scores have now been developed for assessing
everity in several infectious diseases, with the recent addition
f qSOFA in sepsis patients. 28 The use of a single biomarker to
rovide a simple and rapid assessment of disease severity across
ll infectious disease subsets, independently on the etiology of the
nfectious source, may therefore be of significant clinical value. 
This study also found that MR-proADM may play a significant
ole in the triage of fUTI patients. Using a cut-off of 0.80 nmol/L,
R-proADM guided triage could decrease ED admissions and allow
 higher proportion of patients to be safely treated as outpatients.
ndeed, an additional 80 (25.6%) patients could have been treated
n an outpatient basis as opposed to being hospitalized. Further-
ore, the use of such a cut-off resulted in only 2% of outpatient
e-presentations to the ED, as well as no mortalities within 30
ays and no requirement for ICU admission. Despite decreases
n initial hospitalization numbers, results in the original study
sing the PRACTICE score 6 found an unacceptably high admission
ate in patients who were initially deemed suitable for outpatient
reatment. This failure of the PRACTICE guided triage was also par-
ially due to 4 “misdiagnosed” patients with primary bacteremia
rom another source other than the urinary tract. These subjects
ere initially treated as outpatients, but later re-presented to
he ED and were hospitalized. All of these patients with primary
acteremia would have been admitted if the MR-proADM cut-off
as set at 0.80 nmol/L. We therefore consider MR-proADM to
e the optimal biomarker for UTI triage, and 0.80 nmol/L the
ptimal cut-off concerning patient safety, which should be further
xplored in any future clinical interventional trial. 
To our knowledge, only one previous study addressed the use
f MR-proADM for triage decisions in urinary tract infections.
itke et al. described a virtual treatment algorithm combining
 MR-proADM level of 1.5 nmol/L with clinical criteria in UTI
atients, and found a non-significant 7% decrease in hospitaliza-
ion without a corresponding increase in adverse events. 1 The
rimary admission rate of 78% in this cohort of 123 patients was
igh, although 33% of these patients were diagnosed with cystitis,
ossibly due to a higher age and comorbidities as compared to our
ohort. Application of their cut off on our population could have
urther decreased the hospitalization rate. In our cohort, 4 out
f 9 patients in need for ICU admission and 7 out of 12 patients
ho were readmitted after being send home from the ED had an
R-proADM level below 1.5 nmol/L. It is unknown whether these
atients would have met their clinical criteria for hospitalization. 
It should be noted that in a Dutch clinical setting most patients
ith acute febrile UTI consult their general practitioner first, and
re subsequently referred to the ED if required. Based on thearly kinetic profile of MR-proADM in infectious patients, 29,30 
R-proADM may also be of use in the general practitioner’s office
n order to provide guidance concerning hospital referrals. This
n turn could lead to the more efficient use of hospital resources
nd a considerable reduction in costs. Indeed, Dutch general
ractitioners are familiar with point-of-care CRP testing since
ts introduction in primary care, in order to reduce antibiotic
dministration in respiratory tract infections. 31 In this study, we
how that CRP is not a reliable marker in patients with febrile
TI concerning severity, thus, point-of-care testing in a primary
etting should be expanded to MR-proADM. 
The strength of this study lies within its prospective design,
n which both men and women presenting with presumptive
ommunity acquired fUTI were included, thus reflecting the full
pectrum of invasive UTI found at the emergency department.
etailed clinical and microbiological information was recorded in
ach patient, allowing for the adjustment of final diagnosis. A ret-
ospective analysis found that some patients meeting the inclusion
riteria of presumptive fUTI were in fact diagnosed with infections
ther than UTI, but were nevertheless included in our analysis,
ince such diagnostic errors are reflective of real-life patient care.
ndeed, the use of clinical judgment only can often be deceptive
n patients with unspecific symptoms such as fever and back pain.
f these patients could be identified by the use of MR-proADM as
eing bacteremic and separate from the remainder of patients that
ould be safely managed as outpatients, the biomarker could be of
reat use in clinical guidance. 
Our study also has a number of limitations. We included the
RACTICE score in the analysis for the prediction of hospitalization,
ut acknowledge the fact that this endpoint is influenced by the
se of the PRACTICE score in the interventional patient group of
he original study. Implementation of the PRACTICE score, on the
ther hand, will not have affected the prediction of a severe course
f fUTI. A composite endpoint was subsequently created due to
he low number of mortality and ICU admission events within this
tudy, therefore making direct comparisons with end points from
ther studies difficult. Finally, biomarker guided triage can only be
onsidered as hypothesis generating, and potential adverse events
hat would have led to outpatient hospitalization might have been
revented by inpatient care. 
We did not include any clinical parameters in our virtual triage,
ecause reasons for (re)admission were diverse and addition of
anageable number of parameters criteria did not improve our
irtual triage. Optimally, a tool to guide triage designed for the
D should be easy to use. Furthermore, any decision based on a
riage algorithm should be critically appraised for the use in an in-
ividual patient. Clinical conditions such as comorbidity, patients’
reference, compliance, lack of family support cannot easily all
e incorporated in a practicable decision tool. For example, in the
urrent era of rising antimicrobial resistance, the likelihood of a
ausative resistant uropathogen will also influence where and how
o manage fUTI. 32 
In conclusion, we show that the use of MR-proADM can ac-
urately predict the development of severe febrile urinary tract
nfections compared to either PCT or CRP. Consequently, MR-
roADM guided triage can identify patients who may benefit from
 period of hospitalization from those with a low severity infection
ho can be managed as outpatients. Accordingly, resources can be
ocused towards patients with the greatest clinical requirements. 
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